Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bharat Biotech...

    Bharat Biotech acquires GSK Indian arm that produces anti rabies vaccine

    GarimaWritten by Garima Published On 2019-02-18T14:07:50+05:30  |  Updated On 16 Aug 2021 10:50 AM IST

    Hyderabad: Bharat Biotech has recently announced the forthcoming acquisition of Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat from GlaxoSmithKline Asia.


    The company will acquire 100 per cent equity stake in Chiron Behring Vaccines in an all-cash transaction. The deal is intended to complete in the coming weeks. However, the financial figures of the deal remain undisclosed.


    Also Read: Bharat Biotech receives National Technology Award for ROTAVAC® from the President of India



    The move will make Bharat Biotech the world's largest maker of rabies vaccines.

    Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of high-quality rabies vaccines in the world.


    According to the World Health Organization's report, rabies is a vaccine-preventable disease claiming the lives of over 55,000 people each year, mostly in Asia & Africa. India accounts for 36% of the world's rabies deaths.


    Chiron Behring Vaccines is a WHO Pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registrations in more than 20 countries. The rabies vaccine manufactured at Ankleshwar is a result of decades of research & product development.


    Regarding the recent acquisition, the company through a release said, "Bharat Biotech has a wide portfolio of vaccines, with market access to more than 70 countries. The addition of this rabies vaccine will establish Bharat Biotech as a global leader in rabies vaccines manufacturing."


    "Bharat Biotech plans to enhance upon the manufacturing capabilities at Chiron Behring Vaccines and expand market access through product registrations in additional high demand countries," the release added.


    "This acquisition is strategic in helping us enhance our opportunities to achieve greater scale in tackling public health problems. Bharat Biotech will strengthen its product portfolio and substantially increase product availability in response to the growing demand for this vaccine. With the significant disease burden of rabies in India and other countries, I appreciate GSK's vision in this transition to Bharat Biotech, to continue to meet the needs of the patients," said Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, announcing the deal.


    Bharat Biotech is a clone to clinic biotechnology company focused on innovative product development, global manufacturing capabilities and internationally recognised quality management systems. It was the recipient of the National Technology Award for 2018 from the Technology Development Board, Government of India,


    Also Read: WHO grants prequalification to Bharat Biotech's rotavirus vaccine, ROTAVAC

    acquireAcquisitionBharat BiotechChiron Behring VaccinesDepartment of BiotechnologyDr Krishna EllaGlaxoSmithKlineGlaxoSmithKline AsiaGSKnational immunizationprequalificationrabiesrabies vaccineROTAVAC®rotavirusUN agenciesvaccineWHOWorld Health Organization

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok